MassMutual Private Wealth & Trust’s Usana Health Sciences USNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-83
Closed -$2.29K 2461
2025
Q3
$2.29K Hold
83
﹤0.01% 1946
2025
Q2
$2.53K Buy
83
+13
+19% +$369 ﹤0.01% 1884
2025
Q1
$1.89K Sell
70
-30
-30% -$950 ﹤0.01% 1937
2024
Q4
$3.59K Buy
100
+67
+203% +$2.51K ﹤0.01% 1658
2024
Q3
$1.25K Sell
33
-200
-86% -$8.22K ﹤0.01% 1794
2024
Q2
$10.5K Buy
233
+128
+122% +$5.89K ﹤0.01% 1074
2024
Q1
$5.09K Buy
105
+3
+3% +$147 ﹤0.01% 1275
2023
Q4
$5.47K Buy
102
+95
+1,357% +$4.8K ﹤0.01% 1222
2023
Q3
$410 Sell
7
-25
-78% -$1.56K ﹤0.01% 1858
2023
Q2
$2.02K Hold
32
﹤0.01% 1464
2023
Q1
$2.01K Buy
32
+25
+357% +$1.49K ﹤0.01% 1424
2022
Q4
$0 Sell
7
-11
-61% -$596 ﹤0.01% 1866
2022
Q3
$1K Buy
+18
New +$1.19K ﹤0.01% 1550
2022
Q2
Sell
-42
Closed -$3K 1723
2022
Q1
$3K Buy
42
+28
+200% +$2.52K ﹤0.01% 1095
2021
Q4
$1K Buy
+14
New +$1.4K ﹤0.01% 1323

Other funds holding USNA

MassMutual Private Wealth & Trust's USNA Position: Q4 2025 in Review

MassMutual Private Wealth & Trust sold out of Usana Health Sciences (USNA) in Q4 2025, closing a stake of 83 shares — an estimated $2.29K sold.

MassMutual Private Wealth & Trust first reported a position in USNA in Q4 2021 and held it in 15 quarters. The position peaked at $10.5K in Q2 2024. 121 funds tracked by Wall St. Rank hold USNA as of Q4 2025.

  • MassMutual Private Wealth & Trust reported no remaining Usana Health Sciences position as of Q4 2025 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 83 Usana Health Sciences shares in Q4 2025, an estimated $2.29K.
  • MassMutual Private Wealth & Trust first reported a position in Usana Health Sciences in Q4 2021 and held it in 15 quarters.
  • MassMutual Private Wealth & Trust's Usana Health Sciences position peaked at $10.5K in Q2 2024.
  • 121 funds tracked by Wall St. Rank held Usana Health Sciences as of Q4 2025.

Based on MassMutual Private Wealth & Trust's 13F filing for Q4 2025, filed 7 Jan 2026.